A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Saikosaponin A enhances Docetaxel efficacy by selectively inducing death of dormant prostate cancer cells through excessive autophagy
Tekijät: Feng Jiling, Xi Zhichao, Jiang Xue, Li Yang, Nik Nabil Wan Najbah, Liu Mengfan, Song Zejia, Chen Xiaoqiong, Zhou Hua, Dong Qihan, Xu Hongxi
Kustantaja: Elsevier
Julkaisuvuosi: 2023
Journal: Cancer Letters
Tietokannassa oleva lehden nimi: Cancer letters
Lehden akronyymi: Cancer Lett
Artikkelin numero: 216011
Vuosikerta: 554
ISSN: 0304-3835
eISSN: 1872-7980
DOI: https://doi.org/10.1016/j.canlet.2022.216011
Verkko-osoite: https://doi.org/10.1016/j.canlet.2022.216011
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/178973953
Quiescent cancer cells (QCCs), also known as dormant cancer cells, resist and survive chemo- and radiotherapy, resulting in treatment failure and later cancer recurrence when QCCs resume cell cycle progression. However, drugs selectively targeting QCCs are lacking. Saikosaponin A (SSA) derived from Bupleurum DC., is highly potent in eradicating multidrug-resistant prostate QCCs compared with proliferative prostate cancer cells. By further exacerbating the already increased autophagy through inactivation of Akt-mTOR signaling, SSA triggered cell death in QCCs. Contrarily, inhibition of autophagy or activation of Akt signaling pathway prevented SSA-induced cell death. The multicycle of Docetaxel treatments increased the proportion of QCCs, whereas administering SSA at intervals of Docetaxel treatments aggravated cell death in vitro and led to tumor growth arrest and cell death in vivo. In conclusion, SSA is posed as a novel QCCs-eradicating agent by aggravating autophagy in QCCs. In combination with the current therapy, SSA has potential to improve treatment effectiveness and to prevent cancer recurrence.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
